Crinetics Pharmaceuticals, Inc. (CRNX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Crinetics Pharmaceuticals, Inc. reported revenue of $7.70M, up 640.7% from the prior year. The company ran a net loss, with a net margin of -6046.2%. It held $1.13B in total assets against $134.17M in total liabilities.
Key ratios (FY2025)
-6714.8%
Operating margin
-6046.2%
Net margin
-46.9%
Return on equity
+640.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.70M | $1.04M | $4.01M | $0 | $0 | $71.0K | $1.19M | $2.43M | $2.04M | $589.0K |
| Cost of Revenue | $1.08M | $0 | $0 | — | — | — | — | — | — | — |
| Operating Income | -$516.77M | -$338.85M | -$222.61M | -$167.88M | -$107.70M | -$74.95M | -$53.83M | -$28.71M | -$9.13M | -$6.04M |
| Net Income | -$465.32M | -$298.41M | -$214.53M | -$163.92M | -$107.64M | -$73.81M | -$50.42M | -$27.11M | -$9.16M | -$6.02M |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | — | — | — | — |
| Total Assets | $1.13B | $1.43B | $635.35M | $352.18M | $351.01M | $183.44M | $130.38M | $171.41M | $15.60M | — |
| Total Liabilities | $134.17M | $109.79M | $96.25M | $35.85M | $19.07M | $14.53M | $13.24M | $11.19M | $920.0K | — |
| Shareholders' Equity | $992.08M | $1.32B | $539.11M | $316.33M | $331.94M | $168.92M | $117.14M | $160.22M | -$15.02M | -$6.20M |
| Cash & Equivalents | $101.54M | $264.55M | $54.90M | $32.67M | $200.69M | $93.09M | $40.33M | $44.97M | $14.19M | — |
| Operating Cash Flow | -$377.92M | -$230.19M | -$168.60M | -$115.20M | -$88.59M | -$62.03M | -$46.38M | -$19.46M | -$9.48M | -$5.47M |
| Capital Expenditures | $5.76M | $3.84M | $4.69M | $1.66M | $436.0K | $186.0K | $492.0K | $1.06M | $304.0K | $190.0K |
| Shares Outstanding | 95.58M | 92.93M | 68.17M | 53.88M | 47.60M | 33.00M | 24.26M | 24.1K | 1.55M | — |